MESA LABORATORIES INC /CO/ financial metrics
Professional SEC-based dashboard for profitability, financial health, and growth with transparent scoring logic.
Latest period: Q4 2025.
-
Symbol
-
MLAB on Nasdaq
-
Location
-
Lakewood, CO
-
Fiscal year end
-
31 March
-
Latest financial report
-
03 Feb 2026
Shareable Research Card
MLAB - MESA LABORATORIES INC /CO/ Financial Facts
MLAB - MESA LABORATORIES INC /CO/ has a source-backed company facts page for reviewing reported financial metrics, periods, and linked metric histories.
Start with the latest metric summary, then open metric histories or cross-company rankings to compare the same SEC-backed facts.
- Context
- Latest metrics period: Q4 2025
- Latest reported value
- Return On Equity 2.2%
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open metric pages to inspect the reported history.
Return Loop
Why revisit this company facts page
Company facts change as new 10-Q and 10-K filings update the latest reported period, headline values, and cross-company comparison context.
- Latest source-backed update
- Latest metrics period Q4 2025
- Why come back
- Use the next filing cycle to compare new facts against this baseline and then verify the detailed metric history.
- Current latest metrics period: Q4 2025.
- Most recent SEC facts end date on this page: 31 Jan 2026.
- Save this filer to return when the next filing-backed metric period changes the picture.
Freshness comes from the latest SEC company facts period available for this filer and the linked metric history pages.
Latest update
Latest update for MLAB - MESA LABORATORIES INC /CO/
New fact period available
Latest financial period: Q4 2025. Reopen this facts page to verify the newest reported period against the prior baseline.
Update date
03 Feb 2026
Page type
Company facts
Latest period
Q4 2025
SEC-backed company facts were refreshed from filings filed on 03 Feb 2026.
Benchmark Context
How Return On Equity compares
Return On Equity is down about 102% versus the comparable prior period. It sits inside the middle range of the current industry benchmark sample.
Compared with
Compared with MESA LABORATORIES INC /CO/'s recent history and the latest same-industry benchmark sample for the same metric.
Why this is notable
Use the history link to verify the prior-period change, then compare that metric with the current industry middle range if you want broader context.
- Latest comparable period on this page: Q4 2025.
- Current industry benchmark sample: 19 companies.
- Open the metric history first if you want to verify the exact period-to-period change.
Industry benchmark context uses SEC-reported values from the same methodology version. Latest periods may differ across companies.
How to read key metrics on this page
These short guides explain what the headline metrics mean, what to compare next, and where to open the live SEC-backed example for this company.
Plain-English Guide
How to read Revenue on this page
Revenue is the sales a company reports from customers before most expenses are subtracted.
Why people care
People start here to understand business scale and whether demand is growing before they ask about margins or cash flow.
How to read it
Check the latest reported period first, then compare the same quarter or year against prior periods so seasonality does not distort the story.
Compare next
Compare revenue with gross profit, operating income, and operating cash flow to see whether sales are turning into healthy economics.
Revenue can jump because of acquisitions, pricing changes, or revenue-recognition rules, and reporting periods may differ across companies.
Open a live SEC-backed example
Save this filer page
Create a free account to keep this page in your watchlists and return after a new SEC filing changes the record here.
Quick Takeaways
- MLAB - MESA LABORATORIES INC /CO/ financial facts are built from SEC company filings data.
- Latest metrics period on this page: Q4 2025.
- Headline metric: Return On Equity 2.2%.
What Changed
- Return On Equity YoY change: -102%.
- Most recent SEC facts end date: 31 Jan 2026.
Why This Matters
- This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
- Every metric card links to a deeper SEC-backed history page for verification.
Source Evidence
Based on latest 10-Q/10-K
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open company facts to inspect the reported metric history.
See Original Filing
Latest SEC snapshot (2026-01-31) highlights Return On Equity 2.2%, Return On Assets 0.9%, and Operating Margin 7.0%.
Compare This Company Through SEC-backed Metrics
Use these links to compare MLAB - MESA LABORATORIES INC /CO/ against other SEC filers on the same metric, then verify the company history from the paired facts page.
Revenues YoY
Latest value: 4.1%
Financial Quality Score
Transparent 0-100 scoring model based on profitability, financial health, and growth factors.
40.3/100
Caution
Confidence medium
Return On Equity
2.2%
Metric score 0.0/100
Return On Assets
0.86%
Metric score 0.0/100
Financial Health
- Current Ratio
- 1.94x
- Quick Ratio
- 1.27x
- Debt to Equity
- 1.49x
Strengths
Current Ratio and Quick Ratio
Watchpoints
Return On Equity, Return On Assets, and Operating Margin
Key metrics snapshot
Return On Equity
2.2%
YoY: -102%
Industry median:
2.1%
(n=19)
View history
Return On Assets
0.86%
YoY: -102%
Industry median:
0.86%
(n=19)
View history
Operating Margin
7%
YoY: -106%
Industry median:
11%
(n=16)
View history
Current Ratio
1.94x
YoY: +210%
Industry median:
2.15x
(n=19)
View history
Quick Ratio
1.27x
YoY: +201%
Industry median:
1.33x
(n=18)
View history
Debt-to-equity
1.49x
YoY: -21%
View history
Revenues YoY
4.1%
YoY:
View history
Profitability
| Metric |
Latest value |
YoY change |
Industry median |
Calendar period |
Fiscal period |
Unit |
|
Return On Equity
|
2.2%
|
-102%
|
2.1%
(n=19)
|
Q4 2025
|
Q3 2025
|
%
|
|
Return On Assets
|
0.86%
|
-102%
|
0.86%
(n=19)
|
Q4 2025
|
Q3 2025
|
%
|
|
Operating Margin
|
7%
|
-106%
|
11%
(n=16)
|
Q4 2025
|
|
%
|
Financial Health
| Metric |
Latest value |
YoY change |
Industry median |
Calendar period |
Fiscal period |
Unit |
|
Current Ratio
|
1.94x
|
+210%
|
2.15x
(n=19)
|
Q4 2025
|
Q3 2025
|
x
|
|
Quick Ratio
|
1.27x
|
+201%
|
1.33x
(n=18)
|
Q4 2025
|
Q3 2025
|
x
|
|
Debt-to-equity
|
1.49x
|
-21%
|
-
|
Q4 2025
|
Q3 2025
|
x
|
Share Metrics
| Metric |
Latest value |
YoY change |
Calendar period |
Fiscal period |
Unit |
|
Entity Common Stock, Shares Outstanding
|
5,524,813
|
+1.7%
|
Q4 2025
|
Q3 2025
|
shares
|
|
Common Stock, Shares, Outstanding
|
5,524,813
|
+1.3%
|
Q4 2025
|
Q3 2025
|
shares
|
|
Common Stock, Value, Issued
|
$368,555,000
|
+2.8%
|
Q4 2025
|
Q3 2025
|
USD
|
|
Weighted Average Number of Shares Outstanding, Basic
|
5,532,000
|
+1.9%
|
Q4 2025
|
Q3 2025
|
shares
|
|
Weighted Average Number of Shares Outstanding, Diluted
|
5,565,000
|
+2.5%
|
Q4 2025
|
Q3 2025
|
shares
|
Supporting Metrics
These supporting metrics stay fully source-backed for deeper research. Scan the latest value and reported period first, then open a metric page when you need the full filing trail.
| Metric |
Latest value |
YoY change |
Calendar period |
Fiscal period |
Unit |
|
Accounts Payable, Current
|
$5,253,000
|
-8.6%
|
Q4 2025
|
Q3 2025
|
USD
|
|
Accounts Receivable, after Allowance for Credit Loss, Current
|
$40,233,000
|
-4.1%
|
Q4 2025
|
Q3 2025
|
USD
|
|
Accrued Liabilities, Current
|
$15,549,000
|
-37%
|
Q4 2025
|
Q3 2025
|
USD
|
|
Accumulated Other Comprehensive Income (Loss), Net of Tax
|
$1,137,000
|
+88%
|
Q4 2025
|
Q3 2025
|
USD
|
|
Amortization of Intangible Assets
|
$19,675,000
|
+9.5%
|
Q4 2025
|
Q3 2025
|
USD
|
|
Assets
|
$434,849,000
|
+0.35%
|
Q4 2025
|
Q3 2025
|
USD
|
|
Assets, Current
|
$105,632,000
|
+2.9%
|
Q4 2025
|
Q3 2025
|
USD
|
|
Cash and Cash Equivalents, at Carrying Value
|
$28,975,000
|
+6.1%
|
Q4 2025
|
Q3 2025
|
USD
|
|
Common Stock, Shares Authorized
|
25,000,000
|
0%
|
Q4 2025
|
Q3 2025
|
shares
|
|
Common Stock, Shares, Issued
|
5,524,813
|
+1.3%
|
Q4 2025
|
Q3 2025
|
shares
|
|
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
|
$19,219,000
|
|
Q4 2025
|
Q3 2025
|
USD
|
|
Contract with Customer, Liability, Current
|
$14,558,000
|
-1%
|
Q4 2025
|
Q3 2025
|
USD
|
|
Cost of Revenue
|
$93,064,000
|
+4.9%
|
Q4 2025
|
Q3 2025
|
USD
|
|
Deferred Income Tax Assets, Net
|
$1,474,000
|
+7.5%
|
Q4 2025
|
Q3 2025
|
USD
|
|
Deferred Income Tax Liabilities, Net
|
$21,831,000
|
+8.2%
|
Q4 2025
|
Q3 2025
|
USD
|
|
Depreciation
|
$5,343,000
|
-0.35%
|
Q4 2025
|
Q3 2025
|
USD
|
|
Earnings Per Share, Basic
|
0.67
|
|
Q4 2025
|
Q3 2025
|
USD/shares
|
|
Earnings Per Share, Diluted
|
0.65
|
|
Q4 2025
|
Q3 2025
|
USD/shares
|
|
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent
|
0.21
|
0%
|
Q4 2025
|
Q3 2025
|
pure
|
|
Employee-related Liabilities, Current
|
$13,879,000
|
-22%
|
Q4 2025
|
Q3 2025
|
USD
|
|
General and Administrative Expense
|
$75,105,000
|
+6.4%
|
Q4 2025
|
Q3 2025
|
USD
|
|
Goodwill
|
$189,303,000
|
+4.2%
|
Q4 2025
|
Q3 2025
|
USD
|
|
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest
|
$14,068,000
|
|
Q4 2025
|
Q3 2025
|
USD
|
|
Income Tax Expense (Benefit)
|
$10,334,000
|
|
Q4 2025
|
Q3 2025
|
USD
|
|
Inventory, Net
|
$26,559,000
|
+4.7%
|
Q4 2025
|
Q3 2025
|
USD
|
|
Liabilities
|
$248,158,000
|
-9.3%
|
Q4 2025
|
Q3 2025
|
USD
|
|
Liabilities and Equity
|
$434,849,000
|
+0.35%
|
Q4 2025
|
Q3 2025
|
USD
|
|
Liabilities, Current
|
$54,395,000
|
-67%
|
Q4 2025
|
Q3 2025
|
USD
|
|
Nonoperating Income (Expense)
|
$3,164,000
|
+76%
|
Q4 2025
|
Q3 2025
|
USD
|
|
Operating Income (Loss)
|
$17,232,000
|
+38%
|
Q4 2025
|
Q3 2025
|
USD
|
|
Operating Lease, Liability, Current
|
$3,891,000
|
+10%
|
Q4 2025
|
Q3 2025
|
USD
|
|
Other Assets, Current
|
$3,934,000
|
+38%
|
Q4 2025
|
Q3 2025
|
USD
|
|
Other Assets, Noncurrent
|
$17,195,000
|
-6.2%
|
Q4 2025
|
Q3 2025
|
USD
|
|
Other Liabilities, Noncurrent
|
$10,961,000
|
-12%
|
Q4 2025
|
Q3 2025
|
USD
|
|
Property, Plant and Equipment, Net
|
$31,599,000
|
-2.3%
|
Q4 2025
|
Q3 2025
|
USD
|
|
Research and Development Expense
|
$20,157,000
|
+2.7%
|
Q4 2025
|
Q3 2025
|
USD
|
|
Retained Earnings (Accumulated Deficit)
|
$180,727,000
|
+4.3%
|
Q4 2025
|
Q3 2025
|
USD
|
|
Revenue from Contract with Customer, Excluding Assessed Tax
|
$247,541,000
|
+4.1%
|
Q4 2025
|
Q3 2025
|
USD
|
|
Stockholders' Equity Attributable to Parent
|
$186,691,000
|
+20%
|
Q4 2025
|
Q3 2025
|
USD
|
How we score
This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.
| Metric |
Weight |
V1 threshold |
| ROIC | 20 | 5% to 20% |
| ROE | 15 | 8% to 25% |
| ROA | 10 | 2% to 10% |
| Operating Margin | 5 | 5% to 25% |
| Current Ratio | 12 | 1.0x to 2.0x |
| Quick Ratio | 8 | 0.8x to 1.5x |
| Debt to Equity | 10 | 0.3x to 2.0x (lower is better) |
| Revenue YoY | 10 | -10% to +20% |
| Net Income YoY | 10 | -10% to +20% |
How Calculated (standard_v1)
Metrics are computed with a market-consensus convention designed for cross-portal comparability.
- TTM Operating Income / TTM Revenues
- Current Assets / Current Liabilities (latest instant quarter)
- (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
- Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
- TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
- TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
- TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
- TTM Revenues YoY
- TTM Net Income YoY
Explore related SEC datasets